Emily Hayes[email protected]Research GrantBlood biomarkers show risk for preeclampsia in pregnant womenThe proof-of-concept study looked at the levels and ratio of the proteins FK506-binding protein like (FKBPL) and cluster of differentiation 44 (CD44) in plasma of pregnant women and matched normal controls at the Royal Jubilee Maternity Hospital in Belfast, U.K., and how they associated with risk for preeclampsia.July 7, 2020SequencingWeek in Review: Tackling test supply shortages | Should Medicaid cover sequencing in kids? | Pathology case studyDear LabPulse Member,July 2, 2020Trends and FinanceCAP survey: Labs are high on coronavirus test capacity, but still short of suppliesShortages of COVID-19 tests themselves and supplies for testing have been big problems during the public health emergency. Officials in the White House Coronavirus Task Force have said that they would ensure labs had the products they needed amid disruptions in the supply chain.Image courtesy of CAP.Image courtesy of CAP.2021 Cuts to Medicare Pay: What #Pathologists Need to Know. Pathologists need to be aware of upcoming Medicare cuts due to changes to E/M payment and coding, explains @JonathanMyles10 in this CAPcast: https://t.co/j91aZxhvw8. #stopthecutssummer pic.twitter.com/UFX2sjvWKaJuly 1, 2020InfectiousPoint-of-care COVID-19 antibody tests should not be used, experts adviseThe report from an international team of researchers is among the latest to draw attention to flawed serology products. The study evaluated the evidence for different types of antibody tests:July 1, 2020510(k)The case for a national COVID-19 testing strategy: A Q&A with Dr. Gary ProcopThe initial failure of the diagnostic test developed by the U.S. Centers for Disease Control and Prevention (CDC) and distributed to public labs was among the biggest problems with national management of the public health emergency to date. After policies by the U.S. Food and Drug Administration (FDA) were loosened to allow labs to conduct their own tests and companies to introduce products with slight or no review, problems with supply shortages and quality of antibody tests quickly surfaced.June 25, 2020Brain CancerWeek in Review: NCI champions AI | Young adult genetic testing featured at AACR | Liquid biopsy classifies brain cancersDear LabPulse Member,June 25, 2020Cervical CancerMachine learning could 'transform' cervical cancer screening, NCI researchers reportThe NCI researchers described positive experiences with Cytoreader, an automated system for evaluating digital dual-stained whole-slide images for the protein biomarkers p16 and Ki-67, using data from three epidemiology studies of patients with cervical and anal cancers who were positive for human papillomavirus (HPV). The automated system assesses the number of dual-stained positive cells and flags the ones that exceed predefined cutoff points.June 25, 2020Kidney CancerAI-driven DNA methylation liquid biopsy shows promise in brain and kidney cancerThe method -- called cell-free methylated DNA immunoprecipitation and high-throughput sequencing (cfMeDIP-seq) -- has been developed for blood and other kinds of liquid specimens. Testing screens for abnormal methylation, whereas liquid biopsy tests typically look for mutations, the researchers explained.June 23, 2020SequencingBroad genetic testing spots inherited mutations in young cancer patientsThe study evaluated broad-panel genetic blood testing in 1,201 patients between the ages of 18 and 39 who had undergone next-generation sequencing and were treated at Memorial Sloan-Kettering Cancer Research Center. Of the total, 877 had early-onset cancer -- that is, they had tumor types that would normally occur later in life, such as in the breast and colon.June 21, 2020Ovarian CancerWeek in Review: Flurry of FDA actions | Google Health's pathology AI demo | Tool for typing serous ovarian cancerDear LabPulse Member,June 18, 2020Previous PagePage 3 of 27Next PageTop StoriesMonkeypoxSeegene launches 3rd RUO mpox assayAfter introducing two research use only (RUO) mpox assays in August, Seegene has expanded its mpox assay line with a third RUO assay designed to address the spread of the mpox virus variant clade Ib currently prevalent in the mpox outbreak in Africa.Policy and RegulationHospital labs targeted in proposed Calif. hospital licensing regulationsResearch GrantHudsonAlpha Institute gets $2.9M NIH grant for pediatric rare disease sequencingClinical ChemistryADLM releases guidance for blood lipid assessment, lipoprotein testingSponsor ContentVisit our Molecular Diagnostics Community
